(Sofosbuvir 400 mg + Daclatasvir 60 mg)

Darvoni medicine is using for Hepatitis C disease. It’s suitable to treat all genotypes of Hepatitis C.

Darvoni provide an affordable treatment option for HCV delivered to everyone, everywhere all around the globe at a price that many will be able to afford.

Why Darvoni:

Darvoni is a pangenotypic cure for Hepatitis C which combines 400 mg of the pangenotyic NS5B inhibitor Sofosbuvir with 60 mg of the pangenotypic NS5A inhibitor Daclatasvir in a convenient once a day single tablet formulation.There is no need to take Sofosbuvir and Daclatasvir separately.

In addition clinical trials this combination provides cure for over 90% of all patients, 95% for most patients, and for some patient groups perfect 100% have been reported.

This powerful combination is the only one recommended by EASL, AASLD and IDSA to treat all genotypes of HCV.

SVR Rates

The check the expected SVR rate and optimal treatment duration please click following link to decision support tool.

Prescribing Information

Click following link to download the Prescribing Information.

Darvoni offers the advantages of:

Once daily oral single tablet

12 week (84 day) treatment duration for most patients

High cure rates ≥ 90 %

Effective for all HCV genotypes (pangenotypic)

Suitable for patients with cirrhosis and / or co-infection with HIV

Indicated for both treatment naive and treatment experienced patients

Minimal side effects.

Commercial Packaging:

Blister pack: Each box contains 1 blister strip of 6 tablets.

Darvoni (Sofosbuvir 400 mg + Daclatasvir 60 mg) certificate of analysis

Darvoni is available for export direct from the factory. If you are unable to access HCV DAA medication in your country then importing it might well be a good option. Most of all countries allow the legal importation of 12 weeks medication for personal use. Please submit your details on the order page. Therefore our representatives will arrange your shipment.